INTRODUCTION
In an effort to provide treatment guidance regarding a selected group of complex psoriasis scenarios, individuals with a specific interest in psoriatic disease formed a consensus panel and The Delphi method is particularly well suited for addressing healthcare-related issues because the outcome represents the collective judgment of the panel of experts on selected topics. The Delphi method includes three basic characteristics:
(1) repeated individual questioning of the experts; (2) the avoidance of direct confrontation among the experts (e.g., anonymity); and (3) interspersed controlled opinion and feedback.
Importantly, the Delphi method seeks to achieve consensus on complex scenarios where rigorous data are lacking. Available data on a given topic are reviewed extensively, presented, and discussed among the panelists. More importantly, by employing only anonymous voting by the panelists, the Delphi method settles controversy by eliminating the effects of either reputation or ''personality.'' Consequently, anonymous voting after thorough review of the data allows the panelists to vote for what they truly believe, thus avoiding ''groupthink'' and sentiment guided more by ''eminence,'' charisma, and dogmatism.
What follows is an application of the Delphi method for difficult-to-treat clinical scenarios in patients with moderate-to-severe psoriasis. This process occurred in the following three steps over approximately 5 months: (1) selection of difficult-to-treat psoriasis clinical scenarios; (2) selection of potential psoriasis treatment modalities; and (3) the matching, through systematic, iterative rounds of voting, of the clinical scenarios with the most appropriate treatments based on informed assessment of the peer-reviewed literature. At all times, the votes anonymous; thus, at no point was a single individual able to direct the outcome of any aspect of this process. What follows is a reiteration of a process first implemented in 2008 [1] . 
METHOD OVERVIEW
This
Identification Process
The panelists generated a preliminary set of 70 difficult treatment scenarios based on their clinical expertise and experience (Fig. 1) . Next, each scenario was anonymously ranked on a five-point scale ranging from ''very important'' to ''unimportant.'' From this process, 24 topranked scenarios (by virtue of being ranked more important) were selected (Table 1) .
Each panelist was asked to anonymously submit a list of treatments for psoriasis and/or psoriatic arthritis (Food and Drug Administration [FDA] approved, off-label, or investigational yet near likely approval). From this effort, a list of 60 potential treatments was generated ( voting, re-ranking the 10 choices based on their Fig. 1 The Delphi process used to identify and rank treatment options for challenging psoriasis case scenarios. *These discussions occurred before the voluntary withdrawal of efalizumab from the US market. In cases in which efalizumab ranked among the top treatment options, it has been eliminated. ?Six of the cases are presented in this article final assessment of the data. Importantly, treatments that were previously not listed in the top 10 could not be added during the live meeting.
Real-time tabulation and viewing of the final rankings occurred. Panelists also recorded their rankings in a workbook, which allowed confirmation of the electronically acquired data.
After the final ranking, if a treatment option was thought to be medically inappropriate for a given scenario, individual panelists were Each panelist was limited to one challenge during the live meeting.
In the interest of brevity and relevance, six of the 24 considered scenarios are presented in Part 1 of this article. Part 2 of the article will present another five scenarios that were discussed. These selected scenarios were chosen by the first author (B.E.S.).
Statistical Analysis
For comparing three or more groups, Friedman's test was used to rank the data in each set from high to low. Each set of data was ranked separately. The value of the Friedman statistic was calculated from the sums of the ranks and sample sizes. Dunn's multiple comparison post-test was utilized to compare the difference in the sum of ranks between data columns. The calculation of the P-value takes into account the number of comparisons.
Statistical analysis was performed with GraphPadPrism version 5.00 for Windows (GraphPad Software, San Diego CA, USA).
Classification of Experimental Evidence

Supporting a Therapeutic Option
Recommendations from the Agency for Health Care Policy Research (AHCPR) [2] were used to Where definitive scientific evidence was lacking, ''expert opinion'' and consensus (e.g., the community standard) were used for suggested recommendations for key practical issues.
RESULTS
Case Scenario 1: Psoriasis and HPVInduced Cervical or Anogenital Dysplasia
The HPV has a role in many diseases, but the most infamous is cervical cancer. In a study of 3,607 women with cervical cancer, HPV DNA was detectable in 92.5% (grade C evidence) [3] ; however, genotypes 16 and 18 comprise 71% of those cases. In addition, HPV is widely prevalent in the worldwide population.
The presence of HPV DNA has been demonstrated in up to 90% of the lesional skin scrapings of psoriasis patients, and it has been suggested that HPV produces antigens that stimulate psoriatic disease (grade D evidence) [4] . In a case study, Rust et al. suggested a link between psoriasis, light exposure, and HPV in the development of cutaneous squamous cell carcinoma (SCC), as a patient with psoriasis treated extensively with ultraviolet (UV) therapy was found to have HPV serotypes 12 and 17 in some of her cutaneous SCCs (grade D evidence) [5] . Additional patients with psoriasis who were treated with psoralen UVA (PUVA) therapy and methotrexate were found to have HPV-positive SCCs, but the overall copy number and replication activity was low (grade D evidence) [6] . The cumulative effects of UV exposure and immunosuppression must also be considered.
As many of the current psoriasis therapies are immunosuppressants or immunomodulators, selection of an agent for a patient with psoriasis with cervical or anogenital dysplasia is complicated, but there are no specific data addressing this scenario. Retinoids have been tested in cervical intra-epithelial neoplasia (CIN) and were not effective in preventing disease progression (grade A evidence) [7] . A recurrence of condylomata acuminata and a flare of preexisting genital lesions have been reported with etanercept and infliximab, respectively (grade D evidence) [8] . A randomized, placebo-controlled clinical trial evaluating etanercept for pediatric psoriasis also found a higher incidence of skin papillomas/warts; a total of 16 lesions in the treatment group as compared to 0 in the placebo group (grade A evidence) [9] . In light of these data, there is some consensus that tumor necrosis factor alpha infection, but the data supporting this contention are completely lacking.
Discussion
The panel recognized that genital HPV disease typically will be detected by gynecologist/ obstetricians rather than dermatologists, but these clinicians may not recognize or report associations with psoriasis and its therapy. Treatment Challenges: None.
Case Scenario 2: Concomitant Psoriasis and Systemic Lupus Erythematosus
Cases of concomitant psoriasis with systemic lupus erythematosus (SLE) are rare, occurring in only 0.69% of patients with psoriasis and 1.1% of patients with SLE (grade C evidence) [11] . However, subacute cutaneous lupus erythematosus (SCLE) may be mistaken for psoriasis and can coexist with SLE (grade C evidence) [12] . In either case, despite its therapeutic uses in psoriasis, phototherapy is a major concern. Regardless, no published studies exist to guide therapeutic recommendations.
For psoriasis, methotrexate has welldocumented efficacy (grade A evidence) [13] . In SLE, methotrexate decreases the need for steroids and is therapeutic in reducing revised Systemic Lupus Activity Measure (SLAM-R) scores (grade A evidence) [14] .
Acitretin is a psoriasis therapy that has been tested in SLE. For patients with predominantly cutaneous SLE, acitretin has been successful in completely clearing psoriasis in 15 of 20 patients (grade B evidence) [15] . In a separate study, acitretin was found to improve cutaneous lesions in 46% of patients (grade B evidence) [16] .
Cyclosporine has an established role in psoriasis, but it is rarely utilized in SLE due to potential renal toxicity. This agent may be of limited use as a second-line therapy (grade B evidence) [17] or in the settings of lupus-related thrombocytopenia (grade C evidence) [18] and hemolytic anemia (grade D evidence) [19] .
All of the TNF-a agents have significant roles in the treatment of psoriasis and there are a few case reports of benefit in SLE and lupus nephritis (grade D evidence) [20] . However, these therapies have an accepted risk of druginduced SLE (grade D evidence) [21] .
Ustekinumab presents another option given its success in psoriasis, but there are no published studies describing its use in SLE.
For SLE, azathioprine has a long history of use, especially for lupus nephritis (grade B evidence) [22, 23] . Azathioprine also has efficacy in psoriasis, with 55% of patients clearing at least 75% of their psoriasis over a mean of 12 months of therapy, although the supporting literature is over 30 years old (grade B evidence) [24, 25] . Mycophenolate mofetil has growing support as an alternative to azathioprine or as a supplementary medication in SLE and lupus nephritis (grade C evidence) [26] . In addition, there is one open-label study demonstrating modest benefit in psoriasis with 22% of patients reaching a 75% reduction in the Psoriasis Area and Severity Index (PASI) score after 12 weeks (grade B evidence) [27] . Fig. 2 Final results of the voting on case scenario 1, psoriasis with HPV-induced cervical or anogenital dysplasia. a denotes P\0.05 compared with UVB-NB therapy; b denotes P\0.05 compared with UV ? acitretin therapy; c denotes P\0.05 compared with acitretin therapy; d denotes P\0.05 compared with UVB-BB therapy; e denotes P\0.05 compared with MTX therapy. HPV human papilloma virus; MTX methotrexate; TNFI tumor necrosis factor inhibitor; Top topical; UVB-BB broadband ultraviolet B therapy; UVB-NB narrowband ultraviolet B therapy
Hydroxychloroquine also has efficacy in cutaneous lupus, with 50% of patients experiencing improvement (grade B evidence), but its utility in psoriasis is questionable [16] .
There is one report of the successful treatment of psoriasis and SCLE with hydroxychloroquine (grade D evidence) [28] . Yet, there are other reports of hydroxychloroquine causing worsening of psoriasis or pustular flares (grade D evidence) [29, 30] . Another suggested the potential of abatacept as a crossover therapy, as it has been used in rheumatoid arthritis (RA) and is being evaluated for the treatment of psoriatic arthritis.
The agents ranked highest for psoriasis and concomitant SLE were methotrexate, acitretin, azathioprine, methotrexate ? a TNF-a inhibitor, hydroxychloroquine, ustekinumab, cyclosporine, topical steroids ? calcipotriene, and topical steroids. Figure 3 presents the final results of voting on this case.
Treatment Challenges: None.
Case Scenario 3: Severe Psoriatic Nail Disease Causing Functional or Emotional Impairment
In a group of patients hospitalized for psoriasis, up to 78% had psoriatic nail disease. Those with nail findings were significantly older and also a higher incidence of psoriatic arthropathy (grade C evidence) [31] . The majority of patients had both fingernail and toenail involvement with subungual hyperkeratosis as the most common [33, 34] and adalimumab (grade D evidence) [35] have successfully treated psoriatic onycho-pachydermoperiostitis (POPP), a condition that leads to psoriatic onychodystrophy (connective-tissue thickening of the distal phalanx and a periostial reaction).
With therapy, both the nail and joint findings improve significantly, but there is no evidence for efficacy in isolated nail disease outside of POPP. Low-dose cyclosporine led to significant improvement of nail dystrophy in a small set of patients with psoriatic onychodystrophy, although the measure for quantifying nail severity was not described (grade D evidence) [36] . A larger study supported the utility of cyclosporine in psoriatic nail disease alone and in combination with topical calcipotriene under occlusion (grade B evidence) [37] .
Cyclosporine and etretinate have been compared, with each showing very modest efficacy, but the 10-week treatment period examined would be too short to fully evaluate an adequate response (grade A evidence) [38] . A large trial using photo-derived nail psoriasis severity index (NAPSI) scores found significant reductions with etanercept treatment after a 12-week period as compared with controls (grade A evidence) [39] . Infliximab also effectively treats psoriatic nail disease, with 44.7% of patients demonstrating marked improvement at week 50 (grade A evidence) [40] . Ustekinumab also improves nail psoriasis, reducing the NAPSI score by 50% after 24 weeks of continuous therapy [41] . many of those conditions (grade C evidence) [44] . In general, obesity, hypertension, diabetes, hyperlipidemia, and smoking are found at a higher prevalence in the psoriatic population and the prevalence of each risk factor increases as the severity of psoriasis increases (grade B evidence) [45] .
The use of systemic therapies or multiple uses of potent topical corticosteroids have been correlated with higher rates of diabetes and atherosclerosis (grade C evidence) [46] . However, psoriasis may be an independent risk factor for cardiovascular events, specifically myocardial infarction (grade B evidence) [45] . Many studies in the RA population have delved into the assessment of cardiovascular risk. C-reactive protein (CRP), a measure of systemic inflammation, has been the most predictive marker for cardiovascular-related mortality in patients with RA (grade C evidence) [47] . There is evidence for the role of systemic inflammation in cardiovascular risk as these patients have more unrecognized myocardial infarctions as compared to controls, and significantly more events in the 2 years immediately preceding the diagnosis of RA (grade B evidence) [48] . This suggests that systemic inflammation can damage the vascular endothelium and have cardiac consequences well before the joint manifestations of RA. In treating RA, methotrexate has been associated with a decreased risk for acute myocardial infarction, but both oral corticosteroids and biologic agents (etanercept, infliximab, and anakinra) have significantly increased the risk (grade C evidence) [49] . However, another study found that biologics (adalimumab, etanercept, infliximab, and anakinra) were only associated with increased risks when used in combination with other immunosuppressants, and that cytotoxic immunosuppressive agents (e.g., azathioprine, cyclosporine) and oral corticosteroids maintained a significantly elevated risk for cardiovascular events (grade C evidence) [50] . The Consortium of Rheumatology
Researchers of North America (CORRONA) has developed a RA registry of over 10,000 patients. From this cohort, the incidence of cardiovascular events in patients exposed Fig. 4 Etanercept treatment in patients who are obese and diabetic led to significant reductions in systemic inflammatory markers, such as CRP and interleukin-6 (IL-6), but was unable to affect vascular reactivity or insulin sensitivity (grade A evidence) [53] . In patients with the metabolic syndrome, etanercept showed similar effects with its reduction of CRP, IL-6, and fibronectin, but did not alter insulin sensitivity or body composition (grade A evidence) [54] .
Etanercept also has been shown to lower the CRP of prospectively treated patients with moderate-to-severe psoriasis [55] .
In patients with RA refractory to infliximab, short-term adalimumab therapy significantly improved endothelial vasodilatory response and reduced CRP levels (grade C evidence) [56] . In a recent study, both adalimumab and infliximab were shown to improve endothelial function, although common carotid artery intima-medial thickness did not change (grade B evidence) [57] . However, these patients were also on other disease-modifying antirheumatic drugs (DMARDs), which does not allow for conclusions regarding an isolated TNFa-inhibitor effect. Adalimumab has also been shown to increase high-density lipoprotein (HDL) levels while decreasing low-density lipoprotein (LDL), thus creating a favorable cardiovascular risk profile in patients with RA (grade A evidence) [58] .
Infliximab alone exerts a rapid and significant reduction in serum insulin levels and the insulin/ glucose index of patients with RA immediately following infusion (grade C evidence) [56] . Longterm infliximab treatment has also been demonstrated to improve insulin sensitivity (grade C evidence) [59] . For lipid regulation, infliximab therapy has been shown to increase total cholesterol, LDL, and HDL levels without altering the atherogenic ratio (grade B evidence) [60] . However, a separate study demonstrated elevated LDL/HDL and total/HDL-cholesterol ratios, creating a pro-atherogenic lipid profile despite the antiinflammatory effect of infliximab (grade B evidence) [61] . A cohort of patients with RA was studied to determine the incidence of the first cardiovascular event in those treated with either etanercept or adalimumab. There was a significant decrease in the age-sex adjusted [62] . These findings suggest that TNF-a treatments may have the potential to decrease the risk of a patient developing a cardiovascular event.
Discussion
Many panelists expressed concern for the lack of data with various agents on cardiovascular risks inpatients with psoriasis. The majority of the data stems from patients with RA.
Regarding the available choices, the panel agreed that all methotrexate options should include concomitant folic acid. At the time the meeting was held, there were no published data for ustekinumab and its effect on cardiovascular risk. Since the meeting, pooled data from the phase 2 and 3 trials of ustekinumab have shown the drug to have neither a positive or negative effect on major cardiovascular risks [62] . Additional data were presented at the meeting showing that ustekinumab was able to decrease CRP values in patients with psoriasis and had improved efficacy for joint symptoms in those with CRP levels elevated to [0.4 mg/dL prior to therapy (grade A evidence) [63, 64] . However, a poster presentation for another IL-12/23 inhibitor that is structurally similar to ustekinumab (ABT-874 or briakinumab), suggested that drugs that target the p40 subunit of IL-12/23 may increase the risk of major adverse cardiovascular events [65] . Many choices do not have any data for cardiovascular risk (e.g., phototherapy, alefacept alone or in combination with methotrexate); a recognized limitation to the voting.
The panelists voted to include the following treatments as psoriasis therapies that potentially reduce cardiovascular morbidity and mortality:
methotrexate ? TNF-a inhibitor, methotrexate, TNF-a-inhibitor alone, any TNF-a inhibitor with etanercept preferred, any TNF-a inhibitor with adalimumab preferred, any TNF-a inhibitor with infliximab preferred, methotrexate ?
alefacept, ustekinumab, cyclosporine, narrowband UVB phototherapy. It should be noted that cyclosporine may alter lipid profiles unfavorably, and therefore remains a more complex treatment decision in this setting. Figure 5 shows the final results of voting.
Treatment Challenges
(1) Removal of ustekinumab. At the time of this meeting in 2009, ustekinumab was not approved or available in the US for the treatment of psoriasis and panelists expressed concern that there was extremely limited data on its use. Documented cardiovascular events had also occurred in the treatment group in the early trials (two myocardial infarctions and one stroke; grade A evidence) [66] , although there was only one patient who experienced a stroke in the phase 3 trials (grade A evidence) [67] . The However, the group argued that many other choices voted on had even less data or no data regarding cardiovascular risk factors, and ustekinumab remained on the list as a therapeutic option, with 11 participants voting to keep it as opposed to two voting to remove it.
(2) Removal of narrowband UVB therapy.
The suggestion to remove narrowband UVB therapy was based on a lack of evidence for reduction in cardiovascular mortality. However, (grade C evidence) [69] . Polypharmacy is a significant consideration in this group, as it increases the risk for adverse drug events and overall mortality (grade C evidence) [70] . In addition, the incidence of multiple medical problems such as mobility issues, arthritis, stroke, congestive heart failure, glucose intolerance, hypertension, osteoporosis, and malignancy increases with age, thereby influencing which medicines one may prescribe. Importantly, too, the elderly often Few therapies have been studied in an elderly psoriasis population. Pooled data from the clinical trials of alefacept found similar efficacy and adverse event profiles in the elderly as compared to all enrolled psoriasis patients (grade A evidence) [73] . In patients with RA, methotrexate metabolic clearance is inversely proportional to age and further decreases with declines in creatinine clearance (grade B evidence) [74] . For psoriasis, methotrexateassociated myelosuppression may be fatal and is more likely to occur in the elderly (grade C evidence) [75] . The pharmacokinetics of cyclosporine in organ-transplant recipients does not differ significantly with age, but the elderly are still at risk for adverse drug events or the consequences of polypharmacy (grade B evidence) [76] . In elderly patients with RA, the use of TNF-a inhibitors has been associated with an increased risk of new-onset congestive heart failure (CHF) or exacerbation of pre-existing CHF. In those with prior CHF, the risk of death was fourfold higher in TNF-a users as compared to methotrexate users (grade B evidence) [77] .
Discussion
Overall, the data for specific therapies in the elderly psoriatic population are limited. In many of the psoriasis trials, there is an underrepresentation of elderly patients as they are often excluded by comorbidities. The elderly have also experienced a longer duration of disease, which may affect their health prior to therapy and alter their response to treatment.
Many panelists agreed that the therapeutic index is significantly reduced in the elderly. However, if the age-related concerns or risk factors are known, then panelists felt that systemic medications could still be of use in this population. Methotrexate was offered as an example, as it is typically efficacious at a lower dose in the elderly. While this may be due to age-related reductions in creatinine clearance, if this is known prior to the start of therapy, overdoses or adverse events may be avoided.
Attention to polypharmacy is a requirement, as drug interactions may be more likely.
In contrast to methotrexate, other panelists supported the use of TNF-a agents as they may present a safer option when used in the appropriate subset of patients. Of the TNF-a agents, etanercept was highlighted for having the shortest half-life. Acitretin was also discussed as an option at low doses. In respect to disease severity, some proposed having the same treatment modalities available regardless of age. In addition, as many young patients have multiple conditions, comorbidities may dictate treatment rather than age. [88, 89] .
Many panelists stated that the scalp and the rest of the integument should be considered equivalent and agreed that no modifications in the therapeutic regimen were necessary for scalp-specific treatment. One panelist noted that for the few patients with scalp-only involvement, it might be more difficult to attain health insurance approval for costlier systemic medications based on the relatively low body-surface area involvement.
Some panelists noted that they had seen improvement with hair removal on the scalp or 
DISCUSSION
Clinical trials of traditional systemic and biologic treatments for psoriasis exclude a significant proportion of patients with either comorbidities or clinical states that present risk.
The Delphi method was used to clarify the therapeutic approach to 24 important and complex clinical scenarios, which were assigned to a group of expert panelists for detailed review prior to presentation at a live meeting.
Six of these scenarios are presented here;
another five scenarios are presented in Part 2.
The iterative and anonymous voting process of this method depends on an unbiased view of the available clinical data and leads to more objective consensus. This exercise is not meant to be the ''final word'' with regard to therapy for these types of patients, and the numerical ''precision'' of the rankings should not mislead the reader into believing we have created a completely valid ''top-10 list.'' In fact, for example, with reference to any specific patient, the treatment option ranked first might not be ''better'' than those ranked either 5th or 10th.
Instead, the final rankings should be viewed as guidance for practical, potentially effective, and likely safe treatment in a majority of instances. Of course, medical appropriateness of any given therapeutic modality will vary from patient to patient. Because the Delphi method does not introduce better data for a given topic, it cannot produce an idealized outcome. In this vein, the process we have utilized selects rational treatment choices for each clinical scenario, but these choices often are not supported by rigorous studies. At the very least, this evidence-based approach relying on anonymous consensus is a more objective tool for reaching consensus.
An important limitation of this process is that new highly relevant information may be published subsequent to the exercise, which in this case was conducted in 2009. Since that time, for example, efalizumab was voluntarily removed from the US market due to the risk of progressive multifocal leukoencephalopathy (PML) [90, 91] . Another limitation is that some treatment options, such as UV phototherapy, are performed in different settings and guided by different protocols. Specifically, UV phototherapy may be conducted in an office, at a hospital, or at home. Some practitioners might consider tanning beds at commercial The goal in performing this Delphi exercise was to help clinicians in practice benefit from these consensus opinions, offering guidance when presented with patients displaying similar challenging clinical scenarios, and allowing for the use of specific treatment approaches that are effective and safe.
